Chlorzoxazone Tablet
NDC Package 51862-339-01

11-digit billing NDC: 51862033901

Package Information

Chlorzoxazone tablets is chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. This formulation utilizes a tablet delivery system. Marketed by Mayne Pharma Commercial Llc, this product is identified by NDC 51862-339 and is authorized under FDA application ANDA211849.

Identification & Billing

NDC Package Code
51862-339-01
Package Description
100 TABLET in 1 BOTTLE
Product Code
11-Digit Billing Format
51862033901
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Chlorzoxazone
Non-Proprietary Name
Chlorzoxazone
Substance Name
Chlorzoxazone
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Chlorzoxazone does not directly relax tense skeletal muscles in man.

Regulatory & Marketing

Labeler Name
Mayne Pharma Commercial Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA211849
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-31-2020
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51862-339-01 identifies a specific commercial package of 100 tablet in 1 bottle of Chlorzoxazone, a human prescription drug labeled by Mayne Pharma Commercial Llc. This tablet is formulated for oral use and contains chlorzoxazone as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Mayne Pharma Commercial Llc on July 31, 2020. The current certification is valid through December 31, 2027.

How is this Mayne Pharma Commercial Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51862033901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
51862-339-01
11-Digit CMS (5-4-2)
51862-0339-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.